Cover Image

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors

Multiple myeloma (MM) is still a fatal plasma cell cancer. Novel compounds are currently clinically tested as a single agent in relapsing patients, but in best cases with partial response of a fraction of patients, emphasising the need to design tools predicting drug efficacy. Histone deacetylase in...

Full description

Saved in:
Bibliographic Details
Main Authors: Moreaux, Jérôme (Author) , Reme, T. (Author) , Leonard, W. (Author) , Veyrune, J.-L. (Author) , Requirand, G. (Author) , Goldschmidt, Hartmut (Author) , Hose, Dirk (Author) , Klein, B. (Author)
Format: Article (Journal)
Language:English
Published: 18 July 2013
In: British journal of cancer
Year: 2013, Volume: 109, Issue: 3, Pages: 676-685
ISSN:1532-1827
DOI:10.1038/bjc.2013.392
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/bjc.2013.392
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/bjc2013392
Get full text
Author Notes:J. Moreaux, T. Reme, W. Leonard, J.-L. Veyrune, G. Requirand, H. Goldschmidt, D. Hose and B. Klein
Description
Summary:Multiple myeloma (MM) is still a fatal plasma cell cancer. Novel compounds are currently clinically tested as a single agent in relapsing patients, but in best cases with partial response of a fraction of patients, emphasising the need to design tools predicting drug efficacy. Histone deacetylase inhibitors (HDACi) are anticancer agents targeting epigenetic regulation of gene expression and are in clinical development in MM.
Item Description:Gesehen am 07.06.2021
Physical Description:Online Resource
ISSN:1532-1827
DOI:10.1038/bjc.2013.392

Similar Items